Our findings reveal that the β‐catenin/TCF4 complex transcriptionally activates SQLE upon cisplatin treatment, and that SQLE upregulation serves as a prognostic biomarker for survival in HNSCC patients. The gene discussed is TCF4; the disease is head and neck squamous cell carcinoma.